Key result
Pulsed field ablation matches thermal ablation for AF efficacy but carries unique procedural risks.
Why the study?
Pulsed field ablation (PFA) is a novel nonthermal ablation modality with emerging clinical use for atrial fibrillation, but its unique advantages, limitations, and complications require comprehensive evaluation.
What are the clinical advantages, mechanisms of lesion formation, and emerging safety pitfalls of pulsed field ablation compared to thermal ablation in patients with atrial fibrillation?
What are the clinical advantages, mechanisms of lesion formation, and emerging safety pitfalls of pulsed field ablation compared to thermal ablation in patients with atrial fibrillation?
While pulsed field ablation offers a nonthermal alternative to conventional ablation with shorter procedure times, accumulating evidence highlights critical new safety concerns, including hemolysis-related organ injury and coronary vasospasm.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“But I think today we also heard from Boris Schmidt that the ALH syndrome is probably not the best approach. His strategy is to limit the number of applications to 70 or 80, not 150, which is a little too much.”
Requires vigilant hemolysis monitoring and electrode contact during pulsed field ablation; leaves open whether long-term outcomes surpass thermal ablation.
Catheter ablation for tachyarrhythmias was first introduced in the early 1980s using direct‐current (DC) energy. Following the clinical introduction of radiofrequency (RF) ablation in the late 1980s, thermal ablation technologies became the foundation of catheter ablation because of their superior controllability, efficacy, and safety. In 2014, Wittkampf developed a DC‐energy‐delivery catheter system preventing electrical arcing, thereby initiating a modern “revival of DC‐ablation” based on catheter ablation using electroporation. Subsequent development of high‐voltage, short‐duration pulse‐train delivery led to the emergence of pulsed field ablation (PFA). Exposure of myocytes to high‐voltage electric fields induces reversible electroporation through nanoscale pore formation within the lipid bilayer, whereas higher electric‐field delivery produces irreversible electroporation, resulting in permanent membrane disruption, apoptosis, and durable lesion formation. PFA is regarded as a predominantly nonthermal and potentially tissue‐selective ablation modality. Nevertheless, clinical trials of pulmonary vein isolation for atrial fibrillation have demonstrated that PFA is noninferior to conventional thermal ablation strategies, although clear superiority—other than shorter procedural times—has not yet been established. Importantly, recent studies suggest that electrode–tissue contact remains a critical determinant of durable lesion formation. Accumulating evidence indicates that PFA is associated with new complications not commonly observed with thermal ablation, including acute kidney injury, stroke, coronary vasospasm, myocardial ischemia, ventricular fibrillation, and sudden cardiac death. Although the mechanisms remain incompletely understood, hemolysis‐related injury induced by high‐voltage pulse delivery may represent an important contributing mechanism. Development of PFA systems capable of real‐time prediction of irreversible lesion size may be essential for optimizing both procedural efficacy and safety.
No takes yet. Share an insight, caveat, or question.
Nakagawa et al. (2026) conducted a review in Atrial Fibrillation. Pulsed Field Ablation vs. Thermal ablation (radiofrequency or cryoballoon) was evaluated. Pulsed field ablation is noninferior to thermal ablation for atrial fibrillation but carries unique risks like hemolysis and coronary vasospasm, highlighting the need for good electrode contact.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: